Pharma / Biotech

New Support for Checkpoint Agents

Chicago—In the first-line treatment of non-small cell lung cancer (NSCLC), new studies suggest that biomarkers for checkpoint ligand PD-L1 expression and tumor mutational burden (TMB) will guide how they are used.

Source link

Related posts

Comorbidities Can Make Anticoagulation Tricky


QUALITY CHOICE SEVERE COLD AND COUGH NIGHTTIME (Acetaminophen, Diphenhydramine, Phenylephrine) Powder, For Solution [Chain Drug Manufacturing Assn]


Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BIĀ 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World